Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
GSK plc American Depositary Shares (Each representing two Ordinary Shares)
(NY:
GSK
)
58.93
+0.39 (+0.67%)
Official Closing Price
Updated: 7:00 PM EST, Feb 13, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)
< Previous
1
2
...
19
20
21
22
23
24
25
26
27
...
44
45
Next >
10 Health Care Stocks With Whale Alerts In Today's Session
↗
April 26, 2023
Via
Benzinga
3 Biotechs That Might Get Bought Out in 2023
↗
April 26, 2023
Biotech is expected to be a hotbed of mergers and acquisitions this year.
Via
The Motley Fool
Pharma Behemoths GSK, Roche Outplay Covid Declines To Beat Quarterly Calls
↗
April 26, 2023
Both GSK and Roche experienced declining Covid-related sales in the first quarter.
Via
Investor's Business Daily
Was This Acquisition a Savvy Play by This Big Pharma Stock?
↗
April 26, 2023
The British drugmaker picked up a potential blockbuster drug in its deal for Bellus Health.
Via
The Motley Fool
GSK Clocks 10% Growth In Q1 Sales Excluding COVID-19 Products, Reaffirms Guidance
↗
April 26, 2023
Via
Benzinga
Unlocking Xenon Pharmaceuticals $1B Potential: Analyst Cites Anti-Epileptic Candidate's Untapped Value
↗
April 25, 2023
Cantor Fitzgerald has initiated coverage on Xenon Pharmaceuticals Inc (NASDAQ: XENE) with an Overweight rating and a
Via
Benzinga
This Favorable Sign Appears On GSK's Chart
↗
April 14, 2023
Via
Benzinga
This House of Representative Just Sold Up To $100K In GSK Stock
↗
April 05, 2023
Via
Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Spectrum Pharmaceuticals, Inc. (Nasdaq – SPPI), BELLUS Health Inc (Nasdaq – BLU), Prometheus Biosciences, Inc. (Nasdaq – RXDX), Univar Solutions Inc. (NYSE – UNVR)
April 25, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
Why Shares of Arrowhead Pharmaceuticals Are Up Tuesday
↗
April 25, 2023
The clinical-stage biotech announced promising news regarding a potential therapy for inflammatory pulmonary diseases.
Via
The Motley Fool
Second Quarter Outlook For Biotech Stocks
↗
April 25, 2023
Biotech stocks have been consolidating recently but may be ready to rally higher due to factors such as a declining 10-year yield and growing M&A activity.
Via
Talk Markets
Johnson & Johnson Unleashes Kenvue: Tylenol to Neutrogena, $40B Revenue Unit Spinoff Preps for IPO Blitz
↗
April 24, 2023
Via
Benzinga
United Nations' Specialized Agency In Preliminary Talks With Takeda For Dengue Vaccine, Currently Under FDA Review
↗
April 21, 2023
The Pan American Health Organization (PAHO) is reportedly in early talks with Takeda Pharmaceutical Co Ltd (NYSE: TAK) regarding the potential orders of its dengue vaccine, TAK-003.
Via
Benzinga
Why Shares of Bellus Health Skyrocketed This Week
↗
April 20, 2023
The company has received a buyout offer from GSK.
Via
The Motley Fool
GSK reaches agreement to acquire late-stage biopharmaceutical company BELLUS Health
April 18, 2023
From
BELLUS Health Inc.
Via
Business Wire
Why BELLUS Health Stock Is Rocketing Higher Today
↗
April 18, 2023
A $2 billion buyout agreement with GSK is lighting a fire under the biotech's stock today.
Via
The Motley Fool
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: BELLUS Health Inc (Nasdaq – BLU), Prometheus Biosciences, Inc. (Nasdaq – RXDX), Univar Solutions Inc. (NYSE - UNVR)
April 18, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
Bellus Health Soars 98% As GSK Joins Buyout Bonanza With $2 Billion Deal
↗
April 18, 2023
Shares of its takeover candidate nearly doubled on the news.
Via
Investor's Business Daily
Elon Musk Says US Intel Agencies Had Access To Twitter DMs, Alibaba's Ant IPO Might Actually See Light, Airbus Pushes Some 2024 Deliveries: Today's Top Stories
↗
April 18, 2023
Benzinga Elon Musk Drops Bombshell: US Intel Agencies Were Reading Your Twitter DMs
Via
Benzinga
Why Is Bellus Health (BLU) Stock Up 98% Today?
↗
April 18, 2023
Bellus Health (BLU) stock is taking off on Tuesday after the company announced a $2 billion acquisition deal with GSK (GSK).
Via
InvestorPlace
GSK To Strengthen Specialty Medicines and Respiratory Pipeline With $2B BELLUS Health Acquisition
↗
April 18, 2023
Via
Benzinga
Can Pfizer Beat GSK and Moderna in This $10 Billion Market?
↗
April 13, 2023
There's such a big need in preventing RSV that multiple companies should be big winners.
Via
The Motley Fool
Why Shares of Adaptimmune Therapeutics Jumped Tuesday
↗
April 11, 2023
The company bulks up its pipeline by regaining the rights to two of its clinical programs.
Via
The Motley Fool
Biden Administration Launches $5B Program To Boost Development Of Pan-Coronavirus Vaccine, Treatments
↗
April 11, 2023
The White House plans to devote $5 billion to develop effective treatments and vaccines against current and future Covid variants, a Department of Health and Human Services (HHS) spokesperson and a...
Via
Benzinga
Adaptimmune and GSK Have Agreed Terms for Transfer of PRAME and NY-ESO Target Programs back to Adaptimmune
April 11, 2023
- Adaptimmune plans to be IND-ready in 2023 with a PRAME targeted TCR T-cell therapy -- Adaptimmune and GSK will...
Via
Newsfile
Back from the Dead, IBM’s Watson AI is Alive and Re-Emerging
April 10, 2023
While artificial intelligence (AI) seems to have come around full circle in 2023 as ChatGPT finally lit the fuse for full-blown mainstream adoption, Internat
Via
MarketBeat
Topics
Artificial Intelligence
2 Top Biotech Stocks to Buy in April
↗
April 04, 2023
Right now you can pick up these stocks on the dip.
Via
The Motley Fool
Could This Move by Johnson & Johnson Equal Billions for Moderna?
↗
April 02, 2023
An RSV vaccine could be a driver of blockbuster revenue.
Via
The Motley Fool
Texas Judge Obstructs Affordable Act Coverage Mandate For Some Cancer Screenings, Prophylaxis
↗
March 31, 2023
A Texas federal judge reportedly blocked Obamacare's mandate that health insurance plans cover preventive care, including screenings for certain cancers and pre-exposure prophylaxis against HIV (PrEP),...
Via
Benzinga
Stage Set For Generics As Biden Admin Asks Supreme Court To Hear Skinny Labels Case Between GSK, Teva
↗
March 31, 2023
Via
Benzinga
< Previous
1
2
...
19
20
21
22
23
24
25
26
27
...
44
45
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today